C
아이진
185490KOSDAQ자연과학 및 공학 연구개발업52.0 / 100
Reference Date: 2026-04-13
Financial Score23.5 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Ajin is a biotech venture company focused on R&D in medicine and pharmacy, specializing in the development of next-generation innovative therapies such as mRNA-based vaccines and AAV gene therapies. The company is also advancing revenue-generating projects, including meningococcal vaccines and botulinum toxin development, while investing in promising ventures to secure key technologies.
Number of Employees
49people
Average Salary
58.6M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 120.074.0Point
PBR
1.15Industry Average 3.827.0Point
Half of industry avg (excellent)
ROE
-36.31Industry Average -32.113.5Point
In line with industry avg
Debt Ratio
7.00Industry Average 7.524.0Point
In line with industry avg
Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲6.8% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲38.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -30.8% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (11%, downtrend)
Current 1,449Won52-week high 3,40452-week low 1,193
1-month return3.0Point
1m -0.82% (flat)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral정기주주총회결과2026-03-31
- Neutral사업보고서 (2025.12)2026-03-19
- Neutral감사보고서제출2026-03-18
- Neutral의결권대리행사권유참고서류2026-03-17
- Neutral주주총회소집공고2026-03-16